TrialScope solution reduces clinical trial disclosure non-compliance risks, costs

By Melissa Fassbender contact

- Last updated on GMT

TrialScope provides clinical trial transparency and compliance solutions. (Image: iStock/filmfoto)
TrialScope provides clinical trial transparency and compliance solutions. (Image: iStock/filmfoto)
ATLAS Global Compliance is a Software-as-a-Service (SaaS) solution that helps clinical trial sponsors to “disclose locally and comply globally,” says TrialScope CEO.

According to the clinical trial transparency and compliance solutions provider, ATLAS Global Compliance enables sponsors to ensure trials are compliant by consolidating information from all trial sites into one view.

ATLAS Global Compliance reduces risks and costs associated with clinical trial disclosure non-compliance​,” Mark Heinold, CEO, TrialScope, told

ATLAS Global Compliance screenshot. (Image: TrialScope)
ATLAS Global Compliance screenshot. (Image: TrialScope)

The SaaS solution provides clinical trial sponsors with the ability to reference a library of local disclosure rules to guide and prioritize disclosure activities, which Heinold said reduces the costs of “researching and maintaining an organizational understanding of local rules​.”

As Heinold explained, “the real-time views enable sponsors to manage future compliance deadlines while still offering a look back at disclosure performance against policies or regulations​,” he said, adding that the insight is of particular value for companies entering new markets.

Additionally, the solution helps institutionalize requirements information traditionally kept in spreadsheets and local databases.

Many sponsors have robust clinical trial disclosure programs but can’t answer the question, ‘Am I compliant?’ in the markets where they ope​rate,” said Heinold. “ATLAS Global Compliance applies local requirements within the tracking tool to help sponsors to disclose locally and comply globally​.”

Related news

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers